Analyst Confidence High in Erasca (ERAS) Amid Pipeline Advancement and Earlier Q3 2025 Results

ERAS +1.28%

Erasca, Inc. (NASDAQ:ERAS) is one of the 12 hot penny stocks to invest in right now.

On November 14, 2025, Erasca, Inc. (NASDAQ:ERAS) saw Guggenheim’s analyst Michael Schmidt reiterate a “Buy” rating with a $5 price target, following the company’s Q3 2025 results. The analyst highlighted key drivers, including recent Phase 1 trial initiations, additional validation from peer programs, and growing investor anticipation ahead of the first clinical data disclosures in 2025.

A day earlier, on November 12, 2025, Erasca, Inc. (NASDAQ:ERAS) reported its third-quarter 2025 results, posting a net loss of $30.6 million, or $0.11 per share. The company closed the quarter with a solid cash position of $362.4 million, providing a runway into 2028. The company noted a decline in R&D expenses due to a reduction in costs related to clinical trials, preclinical studies, and discovery activities.

Erasca, Inc. (NASDAQ:ERAS) has attracted greater analyst confidence with its progress across multiple programs, including the recent U.S. patent issuance for ERAS-0015 and the ongoing development of ERAS-4001. Positioned as a potential best-in-class therapy, the two developments reflect the company’s strengthening intellectual property portfolio and reinforce expectations around upcoming 2026 Phase 1 monotherapy readouts.

Looking ahead, Erasca, Inc. (NASDAQ:ERAS)’s management remains confident in its long-term growth, thanks to the pending clinical milestones, strengthened scientific leadership, and a robust patent estate.

Erasca, Inc. (NASDAQ:ERAS), a clinical-stage precision oncology company, develops therapies targeting the RAS/MAPK pathway.

While we acknowledge the potential of ERAS as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock.

READ NEXT: 12 Best Commodity Stocks to Buy Right Now and 10 Best Crypto-Related Stocks to Invest In.

Disclosure: None.